AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04373837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neutral googles inducing no-adaptation (NA) associated to Virtual Reality (VR)
Description: The sham condition of this study consists of NA procedure associated to VR task: the pointing task will be followed by 5 sessions of VR task.~Pointing task. Patients will perform a session of 90 pointing movements toward a visual target presented in a variety of positions on the right, the left or at the center of the visual field. This pointing task will be performed with neutral goggles (control condition), which should not induce a shift of the visual field and of spatial attention.~Virtual Reality task consists of a 3D computer-generated virtual environment that will be displayed on a desktop VR computer monitor. A joystick will provide the graphical interface for patients by allowing user-friendly exploration of virtual scenarios. Patients will be presented 16 actions, with dynamic simulations of real life situations. They will verbally estimate and reproduce the duration of each previously presented action.
Study NCT01962311 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lumbar puncture
Description: lumbar puncture at enrollment in study
Study NCT00169845 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha-Tocopherol and Beta-Carotene
Description: Provided by Roche Vitamins Inc.
Study NCT00169845 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Provided by Roche Vitamins Inc
Study NCT00739076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Using Virtual Reality for pain control
Study NCT02311088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Study NCT02311088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02037776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rikkunshito
Description: - Oral administration of rikkunshito (2.5 g t.i.d) before meals for 8 weeks
Study NCT02037776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rikkunshito placebo
Description: - Oral administration of rikkunshito placebo (2.5 g t.i.d) before meals for 8 weeks
Study NCT02881047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CO2 Laser
Description: Perform ablative fractional resurfacing using a 10,600nm carbon dioxide (CO2) laser targeted to thickened, sclerotic plaques causing range of motion limitation and contracture across joints.
Study NCT02881047 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Patients will undergo ultrasound of the planned treatment site to measure skin thickness and blood flow via Doppler ultrasound.
Study NCT02881047 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Skin Biopsy
Description: standard 4mm punch biopsy of the skin at the planned treatment site for histologic assessment of skin thickness and sclerosis.
Study NCT02895321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cavex Bite&White ExSense
Description: a water-based mint aroma gel containing hydroxyapatite and potassium nitrate.
Study NCT02437643 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dairy Protein
Description: Participants will be provided dairy products: WL-LoEx will be provided 1 dairy serving per day and Pro-WL-LoEx will be provided 8 dairy servings per day.
Study NCT02437643 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity exercise
Description: Participants in both groups will participate in chair exercises 3 times a week.
Study NCT02437643 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Low intensity exercise
Description: Participants in both groups will participate in chair exercises 3 times a week.
Study NCT00419159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Description: Everolimus was supplied in 5 mg tablets in blister packs.
Study NCT02895321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate, Protection Caries
Description: a fluorine-based toothpaste gels
Study NCT02895321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo gel
Description: a glycerin and water gel
Study NCT04131764 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Reflex (Brightlamp Inc., Purdue University)
Description: The Reflex pupillometer is a mobile based application that provides a quantitative way to monitor pupillary activity and responsiveness. It uses the mobile phone as a source of light and records pupillary response, as well as analyzes and compiles the data. It produces quantitative measures such as latency, minimum and maximum pupil diameter, maximum and average constriction velocity, dilation velocity, and 75% recovery time.
Study NCT01214421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Description: Tablets of 15 or 30 mg
Study NCT00332969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide
Study NCT02744339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat
Description: Adempas up-titrated to max. 1.5mg TID
Study NCT02744339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sham-titrated TID
Study NCT02574962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.P. Acthar® Gel
Study NCT02508597 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Physicians receiving smoking cessation training
Description: On the training day, the investigators will explain at the beginning of the workshop the purpose of the training, and the details of the brief smoking cessation intervention to all physicians who attend the training workshop.
Study NCT03545412 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microfocused ultrasound with visualization
Description: Each subject to receive a minimum of 800 treatment lines, on two planes of treatment using the 4-4.5mm and 7-3.0mm transducer depths
Study NCT03051893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chronocort
Description: Modified formulation of hydrocortisone
Study NCT01642147 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Doppler (TCD)
Description: A 2-MHz Transcranial Doppler probe (MULTI-DOP P2.2C; DWL, Elektronische Systeme GmbH, Germany) will be used to measure both sides of Vmca of both patients undergoing craniotomy and patients undergoing abdominal surgery. The signal will be range-gated to a depth of 45 to 60 mm at temporal bone window to achieve the optimal signal according to standard techniques. The measures will be recorded in the operation room before anesthesia, in the recovery room at extubation, 30, 60, 90, and 120 min after extubation.
Study NCT01642147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler (TCD)
Description: A 2-MHz Transcranial Doppler probe (MULTI-DOP P2.2C; DWL, Elektronische Systeme GmbH, Germany) will be used to measure both sides of Vmca of both patients undergoing craniotomy and patients undergoing abdominal surgery. The signal will be range-gated to a depth of 45 to 60 mm at temporal bone window to achieve the optimal signal according to standard techniques. The measures will be recorded in the operation room before anesthesia, in the recovery room at extubation, 30, 60, 90, and 120 min after extubation.
Study NCT01642147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: jugular venous bulb catheterization
Description: After local anesthesia, a jugular venous bulb catheter(16G, manufactured by Arrow International Inc. USA) will be placed in the dominant side. The proper placement of the tip of the catheter in the jugular bulb will be confirmed later by a postoperative lateral skull X-ray. SjvO2 (blood sample will be drawn slowly at a speed of 2ml per minute) will be measured before anesthesia, at extubation, 30, 60, 90, and 120 min after extubation.
Study NCT01642147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor removal surgery under general anesthesia
Description: Surgery types include total or subtotal removal of tumors.For all surgical procedures, general anesthesia will be maintained with isoflurane (0.5-1.0 minimal alveolar concentration (MAC) expired), repeated boluses of fentanyl (1\~2 µg/kg IV), and continuous vecuronium 50～70 IV. All patients will be mechanical ventilated with oxygen. During anesthesia, blood pressure and heart rate will be kept stable, within ±10% of the preoperative levels. Hematocrit (Hct) will be maintained higher than 30%. After surgery, tracheal extubation will be performed when patients regain full muscle strength, breathe spontaneously with acceptable oxygenation and normocapnia.
Study NCT01642147 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radial artery catheterization
Description: After local anesthesia, an intra-arterial pressure line(I.V. catheter and pressure line kit are both manufactured by Smiths Medical International Ltd. USA) will be inserted in radial artery. Sample blood will be drawn from the line before anesthesia, at tracheal extubation, and 30, 60, 90, 120 min after tracheal extubation.
Study NCT01642147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radial artery catheterization
Description: After local anesthesia, an intra-arterial pressure line(I.V. catheter and pressure line kit are both manufactured by Smiths Medical International Ltd. USA) will be inserted in radial artery. Sample blood will be drawn from the line before anesthesia, at tracheal extubation, and 30, 60, 90, 120 min after tracheal extubation.
Study NCT01642147 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal surgery under general anesthesia
Description: For all surgical procedures, general anesthesia will be maintained with isoflurane (0.5-1.0 minimal alveolar concentration (MAC) expired), repeated boluses of fentanyl (1\~2 µg/kg IV), and continuous vecuronium 50～70 IV. All patients will be mechanical ventilated with oxygen. During anesthesia, blood pressure and heart rate will be kept stable, within ±10% of the preoperative levels. Hematocrit (Hct) will be maintained higher than 30%. After surgery, tracheal extubation will be performed when patients regain full muscle strength, breathe spontaneously with acceptable oxygenation and normocapnia.
Study NCT02772562 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-V/F
Description: 0.5 ml containing at least 2 x 108 Infectious Units (Inf.U) PROSTVAC-V given on day 1.~0.5 ml containing at least 1 x 109 Inf.U PROSTVAC-F given on days 15, 28, 57, 85, 113, 141.
Study NCT03783689 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SPRINT Peripheral Nerve Stimulation (PNS) System
Description: The SPRINT System delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator).
Study NCT03783689 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SPRINT Peripheral Nerve Stimulation (PNS) System
Description: The SPRINT System delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes two small wires (called Leads) that are placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator).
Study NCT03843398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colorectal cancer resection via minilaparotomy
Description: According to the cancer location, a 7 cm incision is made in specific area of the patient's abdomen. The whole procedure of operation will be finished within this incision. If the incision must be lengthen due to the surgical demand, the failure of the minilaparotomy is determined.
Study NCT03843398 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic colorectal cancer resection
Description: This is one of the routine procedures used for colorectal cancer resection.
Study NCT03941899 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Levobupivacaine in QLB II
Description: Quadratus Lomborum Block II type will be performed by injecting levobupivacaine 0.375% 20 ml between latissimus dorsi and quadratus lomborum muscle.
Study NCT01779453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ETC-1002
Description: Week 1-2, 60 mg/day; Week 3-4, 120 mg/day; Week 5-6, 180 mg/day; Week 7-8, 240 mg/day
Study NCT01779453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily for 8 weeks
Study NCT01779453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 10mg once daily for 8 weeks
Study NCT01779453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Atorvastatin 10mg once daily for 8 weeks
Study NCT02670122 — intervention group
Intervention type: DEVICE
Intervention: DEB-TACE
Description: Selective and ultraselective transcatheter intraarterial administration up to 3ml of well calibrated 100µ drug eluting microspheres with up to 150 mg of doxorubicin.
Study NCT04622098 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic ultrasound
Description: this is an endoscopic procedure for the assessment of the lesions, the following will be recorded:~1. the tumor location,~2. layer of origin,~3. maximal diameter,~4. regularity of extraluminal border,~5. echopattern,~6. presence of cystic spaces or echogenic foci.
Study NCT01303315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TANTALUS System
Description: An Active Implantable Pulse Generator Medical Device for the treatment of Obesity and Diabetes Type 2 and Obesity
Study NCT01303315 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TANTALUS System
Description: An Active Implantable Pulse Generator Medical Device for the treatment of Obesity and Diabetes Type 2 and Obesity
Study NCT01303315 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TANTALUS System
Description: An Active Implantable Pulse Generator Medical Device for the treatment of Obesity and Diabetes Type 2 and Obesity
Study NCT02626247 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin A +Long chain PUFA
Description: 3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
Study NCT02626247 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
Study NCT02808247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: Pharmaceutical form: Soft gelatine capsule Pharmaceutical code: Nintedanib (BIBF1120) Source: Boehringer Ingelheim Pharma GmbH \& Co. KG Unit strength: 100 mg and 150 mg capsules Daily dose: 400 mg (200 mg twice daily p.o.) Route of administration: oral
Study NCT02178358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2157299
Description: Administered orally
Study NCT02178358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Administered orally
Study NCT02178358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sorafenib
Description: Administered orally
Study NCT02178358 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT03695328 — intervention group
Intervention type: BEHAVIORAL
Intervention: physical activity level
Study NCT03695328 — intervention group
Intervention type: BEHAVIORAL
Intervention: Dietary Intake
Study NCT03287011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shoplaq toothpaste
Description: ACTIVE INGREDIENT Sodium Monofluorophosphate 1000 PPM INGREDIENTS Precipitated Calcium Carbonate, Sorbitol, Glycerin, Precipitated Silica, Sodium Carboxy Methyl Cellulose, Sodium Benzoate, DM Water, Colour CI-45410, Holy Basil Oil, Neem Oil, Citrus Oil, Thymol Oi, Clove Oil, Piper Betel Leaf Oil, Tea Tree Oil, Eucalyptus Oil, Peppermint Oil, Spearmint Oil.~Dye containing tooth paste for disclosing plaque and efficient brushing for better oral health.
Study NCT03287011 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colgate toothpaste
Description: fluoridated
Study NCT02839382 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coaching
Description: An external facilitator or coach is assigned 15-20 primary care clinics and will make face-to-face site visits and monthly phone calls for 15 months to support building QI capacity in each assigned practcie
Study NCT02808247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ifosfamide
Description: Ifosfamide will be given at a dose of 3 g/m2 intravenously on days 1, 2 and 3 every 21 days. The total dose per cycle is 9 g/m2
Study NCT01889069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered at a dose of 1400 mg SC once a month for at least 4 doses during the Induction period, and at a dose of 1400 mg SC once every two months for at least 6 doses during the Maintenance period.
Study NCT01889069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as per standard local practice as a part of standard chemotherapy regimen.
Study NCT01889069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine will be administered as per standard local practice as a part of standard chemotherapy regimen.
Study NCT01889069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered as per standard local practice as a part of standard chemotherapy regimen.
Study NCT01889069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered as per standard local practice as a part of standard chemotherapy regimen.
Study NCT01889069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine will be administered as per standard local practice as a part of standard chemotherapy regimen.
Study NCT00830687 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: TARGON FN
Description: The Targon FN implant consists of a small side plate with six locking screw ports
Study NCT02528851 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extubation from endotracheal mechanical ventilation to CPAP
Description: Following randomization, the infants will be extubated to the higher CPAP group (CPAP level 2cm H2O higher than extubation EAP) or equivalent CPAP group (CPAP level equal to the extubation EAP) based on their allocation.
Study NCT02528851 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extubation from endotracheal mechanical ventilation to CPAP
Description: Following randomization, the infants will be extubated to the higher CPAP group (CPAP level 2cm H2O higher than extubation EAP) or equivalent CPAP group (CPAP level equal to the extubation EAP) based on their allocation.
Study NCT01426347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sugar pill
Description: Intervention includes 1 sugar pill once a week for 16 weeks dispensed as a capsule.
Study NCT01426347 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergocalciferol
Description: Ergocalciferol 50,000 IU per week for 16 weeks
Study NCT02839382 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Outreach
Description: Practices randomized to this arm of the study will receive an educational outreach phone call by an academic expert on implementation strategies for use of a cardiovascular risk calculator within their daily work flow and clinic setting
Study NCT02839382 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Site Visits
Description: Practices randomized to this arm of the study will be given an opportunity to make a site visit to an exemplar practice to learn about innovative approaches to conducting quality improvement activities.
Study NCT01456364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: A loading dose of 180 mg of ticagrelor is administered followed by 90 mg maintenance doses twice daily
Study NCT01456364 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: A prasugrel loading dose of 60 mg is administered followed by a 10 mg per day maintenance dose for patients \< 75 years or a 5 mg maintenance dose per day for patients >= 75 years
Study NCT00840697 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercises and work related rehabilitation
Description: Treatment in groups, twice a week for 3 weeks. The treatment includes exercises, cognitive intervention and work related rehabilitation. The exercises include fitness, strength and stretching
Study NCT00840697 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief intervention
Description: 1 consultation at the physiotherapist, which give advice Summary talk with the physician about activity and work when having neck- and low back pain
Study NCT00840697 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: multidisciplinary exercise group
Description: 10 days during 3 weeks. Treatment in groups, exercise and cognitive treatment
Study NCT01385956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOM 230 LAR
Description: We will attempt dose escalation starting at a lower level 1 of 40 mg since we are using SOM 230 LAR in combination with gemcitabine for the first time.
Study NCT01385956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Fixed dose: 1000mg/m\^2 weekly x3 then 1 week off